0HA3.L - Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.
100 Cardinal Way
Redwood City, CA 94063
United States
(650) 656-9323
https://adverum.com
Sector(s):
Industry:
Full-time employees: 123
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Dr. Laurent Fischer | Pres, CEO & Director | 977.23k | N/A | 1964 |
| Ms. Linda M. Rubinstein M.A. | CFO, Principal Financial Officer & Principal Accounting Officer | 111.89k | N/A | 1967 |
| Mr. Kishor Peter Soparkar J.D. | Chief Operating Officer | 656.96k | N/A | 1971 |
| Mr. John W. Rakow J.D. | Sr. VP & Gen. Counsel | 954.24k | N/A | 1957 |
| Dr. Setareh Seyedkazemi Pharm.D. | Chief Devel. Officer | 834.57k | N/A | 1974 |
| Mr. Heikki Jouttijarvi | Sr. VP & Head of Technical Operations | N/A | N/A | N/A |
| Dr. Brigit Riley Ph.D. | Chief Scientific Officer | N/A | N/A | 1978 |
| Ms. Dena House | Sr. VP of HR, Organizational Devel. & Learning | N/A | N/A | N/A |
| Ms. Carla Fiankan | Sr. VP of Regulatory Affairs | N/A | N/A | N/A |
| Dr. Jim Wang Ph.D. | Chief Regulatory Officer | N/A | N/A | N/A |
Description
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Corporate governance
Adverum Biotechnologies, Inc.’s ISS governance QualityScore as of 1 June 2023 is 7. The pillar scores are Audit: 5; Board: 5; Shareholder rights: 8; Compensation: 9.
